- Isis' financing vehicle supports CV/metabolic development
- Isis, Ortho-McNeil sign metabolic drug development deal
- Genzyme and Isis enter $1.2bn CV collaboration
- Symphony Neuro licenses Guilford's GPI 1485
- MGI Pharma to buy Guilford Pharmaceuticals for $174mm
- Eisai buys MGI Pharma
- Exelixis gets additional funding for GSK deal
- Alexza forms financing vehicle to support CNS agents
- Dynavax gets $50mm in special funding from Symphony
- Merck licenses Heplisav rights from Dynavax; ends
- Symphony financing to support OxiGene cancer, eye programs
- Symphony finances development of three Lexicon candidates; Lexicon later reacquires development rights
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.